-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $41

Benzinga·11/05/2026 20:09:07
Listen to the news
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $38 to $41.